Smith & Nephew Share Chat (SN.)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Smith & Nephew	LSE:SN.	London	Ordinary Share	GB0009223206	ORD USD0.20

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-13.50p	-1.05%	1,266.50p	1,265.50p	1,266.00p	1,287.50p	1,258.00p	1,281.50p	3,539,964	16:35:02

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	3,527.9	650.8	65.0	19.0	11,095.42

Smith & Nephew Share Discussion Threads

Showing 801 to 825 of 825 messages

Chat Pages: 33 32 31 30 29 28 27 26 25 24 23 22 Older

Date	Subject	Author	Discuss
26/7/2018 07:42	Accounts our for 1/2 year - Very much steady as she goes - https://www.investegate.co.uk/smith---38--nephew-plc--sn--/rns/half-year-report/201807260700188013V/ Nothing to shout about (imo) share price reaction will very much depend on forecasts (anyone got them?)	pugugly	Read Full Thread Reply
04/5/2018 08:24	Elliott called for the company to be broken up last year, after which Mr Bohuon unveiled a cost-cutting plan which he said would deliver $160m of savings by 2022.Analysts at Bernstein said: "S&N's overall performance on both growth and margins has remained disappointing. From here it is all about execution." Daily Telegraph	steeplejack	Read Full Thread Reply
03/5/2018 10:49	Yes , got to be only a matter of time.	its the oxman	Read Full Thread Reply
03/5/2018 09:28	Something has to happen here. These guys are vulnerable now. Would not be surprised if Elliot Management makes a return.	basil brush1	Read Full Thread Reply
03/5/2018 08:25	These less than brilliant results would make it an opportune time to strike for a possible bidder.	broadwood	Read Full Thread Reply
03/5/2018 08:17	The guidance has been trimmed from revenue growth of 3-4% at the time of the finals to 2-3% now.The suggestion is that things will stabilise and return to a more normal pattern in the rest of the year.Emerging markets are encouraging.Whether this update is worth over 7% off the share price is questionable especially given the corporate activity just now in the sector.Yet the shares have been very strong of late and are vulnerable to top slicing.Maybe I'm too simplistic but I never really worry about my holding in Smith & Nephew.I always feel that if things take an enduring turn for the worse,someone will take the company over.	steeplejack	Read Full Thread Reply
03/5/2018 07:43	I think you are too pessimistic. I am seeing a P/E of 20 on 2018 EPS before this update, while Stryker is 26. Emerging markets growing at 9% and SN has very little debt.	basil brush1	Read Full Thread Reply
03/5/2018 07:25	Flat earnings and a P/E of 22 hardly makes it remotely attractive. Also I see plenty of alternative wound care therapies coming through in coming years. Look at Origin WW as an example. Technology been given fast track approval by FDA.	rock star	Read Full Thread Reply
23/4/2018 19:35	I bought these on the bid speculation awhile back. This sounds interesting. Smith & Nephew was top of the blue chip pile as Dutch giant Philips' first-quarter results revealed strong growth in medical equipment, which was music to the ears of the London-listed maker of artificial shoulders, knees and possibly toes. A further tonic for S&N shares was bid speculation bubbling up again as City traders pointed to US-based Stryker, based in the marvellously named Kalamazoo, Michigan, being a possible suitor after four years ago confirming it had been been looking at a potential takeover.	broadwood	Read Full Thread Reply
23/4/2018 15:48	Why today? News?	its the oxman	Read Full Thread Reply
23/4/2018 15:43	Is this the big breakout?	basil brush1	Read Full Thread Reply
04/4/2018 16:13	Any views on new CEO? He sold Alere to Abbott in 2017 for $5.3 billion. No one seems to care?	basil brush1	Read Full Thread Reply
24/1/2018 08:00	Scope to have a run back over 1300p with lower tax guidance.	its the oxman	Read Full Thread Reply
22/1/2018 10:20	Strykers full results are on Jan 30, the next few weeks will be interesting. Stryker provides 2017 preliminary net sales results By GlobeNewswire, January 09, 2018, 08:15:00 AM EDT Kalamazoo, Michigan - January 9, 2018 - Stryker Corporation (NYSE:SYK) announced today that preliminary results for the fourth quarter and full year 2017 were: Preliminary Fourth Quarter Highlights Net sales grew 10.0% to $3.5 billion (8.7% constant currency) Orthopaedics 8.1 % or 6.8 % constant currency MedSurg 10.9 % or 9.8 % constant currency Neurotechnology and Spine 11.5 % or 10.3 % constant currency Preliminary Full Year Highlights Net sales grew 9.9% to $12.4 billion (9.8% constant currency) Orthopaedics 6.6 % or 6.5 % constant currency MedSurg 13.6 % or 13.4 % constant currency Neurotechnology and Spine 8.2 % or 8.3 % constant currency Preliminary consolidated net sales of $3.5 billion and $12.4 billion increased 10.0% and 9.9% as reported in the fourth quarter and full year. Excluding the impact of foreign currency and acquisitions, net sales increased 8.1% and 7.1% in the fourth quarter and full year. Based on our year-to-date performance, we expect 2017 adjusted net earnings per diluted share(a) to be toward the high end of our previously announced range of $6.45 to $6.50. The foreign currency exchange impact on net sales in the fourth quarter was positive of approximately 1.2% and nominal in the full year. "We continued our momentum with strong organic sales growth of 8% for the fourth quarter and 7% for the full year," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I would like to thank our teams for delivering these results, which were well balanced across businesses and geographies. We are also driving innovation through R&D and acquisitions that will fuel future growth. These investments will enable us to deliver sales growth at the high end of med tech and leveraged earning gains."	basil brush1	Read Full Thread Reply
22/1/2018 10:16	Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on.	basil brush1	Read Full Thread Reply
21/1/2018 12:42	Bloody well hope there is a bid. Sold a load just under 1400p and now bought them back and more besides. Poor performer over 12 months. Hoping for a bounce regardless with results. We will see.	its the oxman	Read Full Thread Reply
19/1/2018 08:39	imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period.	basil brush1	Read Full Thread Reply
18/1/2018 16:25	Could have further to fall (imo) 11-Oct-17Citigroup Sell Now 1,233.50 Then 1,359.00 New target 1,160.00	pugugly	Read Full Thread Reply
17/1/2018 11:18	these were 1440 less than 3 months back. are the powers than be managing the price down so to get a bid in at not much higher than the October highs?	basil brush1	Read Full Thread Reply
16/1/2018 20:07	As a quality operator surely SN will get some bid speculation this year. Must be so tempting now it's slipped back to 1250p.	its the oxman	Read Full Thread Reply
05/1/2018 12:29	nice to finally see a rally. S&N has underperformed stryker by 75% over two years in dollar terms. S&N ADRs are unchanged while stryker has gone up by 75%. unbelievable.	basil brush1	Read Full Thread Reply
02/1/2018 21:54	this is a real dog stock. having tracked stryker closely for decades, this has incredibly under-performed by a massive 75% in the last two years. three years ago stryker was only slightly bigger than S&N, now it is four times the size.	basil brush1	Read Full Thread Reply
15/12/2017 14:05	Anyone know why these are trading at such a big discount to Stryker? Is it because SN does not have enough debt on board? I have SN on a PE ratio of 18 from Google Finance, with SYK at 35.	basil brush1	Read Full Thread Reply
13/12/2017 14:58	these shares seem to have dodgy knees.... anyone know what happened with Elliot Advisors? http://www.telegraph.co.uk/business/2017/11/03/smith-nephew-boss-defends-strategy-elliott-circles/	basil brush1	Read Full Thread Reply
13/11/2017 12:15	Dodgy knees and hips aren't going away - keep buying.	its the oxman	Read Full Thread Reply

Chat Pages: 33 32 31 30 29 28 27 26 25 24 23 22 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.